HOLX 26.96 Hologic Inc $HOLX Hit a 52 week high of 27.13 Closing the day 11/03/14 at 26.96 +0.77 +2.94% With a day low of 26.56 and a total volume of 5,570,184.
HOLX Recent Posts: http://investorshangout.com/Hologic-Inc-HOLX-54363/
HOLX Hologic Inc Recent Headline News
The Centers for Medicare and Medicaid Services Issues Ruling on 2015 Reimbursement Rates
PR Newswire - Fri Oct 31, 9:28PM CDT
Hologic, Inc. (NASDAQ: HOLX) announced today that the Centers for Medicare and Medicaid Services (CMS) has released reimbursement rates for screening and diagnostic 3D mammography. The action establishes national average payment rates for the Category I Current Procedural Terminology (CPT) code for 3D screening mammography and creates a new add-on Healthcare Common Procedure Coding System (HCPCS) code for 3D diagnostic mammography.
HOLX: 26.96 (+0.77)
Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 43.29 (-0.30), MDT: 68.15 (-0.01), COV: 92.42 (-0.02), RMD: 51.71 (-0.51), HOLX: 26.96 (+0.77)
Is Haemonetics (HAE) Poised to Beat on Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:15PM CDT
Haemonetics (HAE) has delivered positive earnings surprises in three of the past four quarters with an average beat of 1.9%
HAE: 34.74 (-2.98), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Can Qiagen (QGEN) Surprise Earnings Estimates in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:17PM CDT
In Japan, Qiagen (QGEN) performed impressively in the first half of 2014 on a year-over-year basis.
QGEN: 23.70 (+0.24), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Luminex Tops Q3 Earnings, Revenues in Line; Outlook Weak - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:40PM CDT
Luminex Corporation's (LMNX) earnings per share jumped sharply to 22 cents from a penny in the year-ago quarter driven by strong revenue growth and margin expansion.
BDX: 127.42 (-1.28), LMNX: 18.78 (-0.22), AFFX: 9.18 (+0.17), HOLX: 26.96 (+0.77)
Upgrade Alert for Hologic (HOLX)
Comtex SmarTrend(R) - Tue Oct 28, 6:58AM CDT
Hologic (NASDAQ:HOLX) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $25.21 on volume of 2.5 million shares, below average daily volume of 2.7 million. Over the past year, Hologic has traded in a range of $13.90 to $26.75 and closed yesterday at $25.21, 81% above that low. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has declined 0.2%.
HOLX: 26.96 (+0.77)
Can Ecolab Inc. (ECL) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:58PM CDT
Our proven model does not conclusively show that Ecolab Inc. (ECL) is likely to beat earnings this quarter.
HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68), ECL: 110.10 (-1.13)
Is LabCorp (LH) Likely to Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:20PM CDT
Laboratory Corp. of America Holdings (LH) is scheduled to release its third-quarter 2014 results before the opening bell on Oct 28.
LH: 101.23 (-8.06), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Axial and Peripheral Bone Densitometers - 2014 Global Strategic Business Report.
M2 - Fri Oct 24, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3fz9n/bone) has announced the addition of the "Bone Densitometers - Global Strategic Business Report." report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 18 companies including many key and niche players. This report analyzes the worldwide markets for Bone Densitometers in Units and US$ Thousands by the following Product Segments: - Axial Bone Densitometers - Peripheral Bone Densitometers Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Factors 3. Reimbursements: Vital For Market Expansion 4. Product Overview 5. Osteoporosis: An Overview 6. Bone Densitometry Alternatives 7. Osteoporosis Drug Market - Impact On Diagnostics 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape - Total Companies Profiled: 18 (including Divisions/Subsidiaries - 19) - The United States (5) - Japan (1) - Europe (
- - France (2) - - Germany (1) - - The United Kingdom (1) - - Italy (1) - - Spain (1) - - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) - Middle East (1) Companies Mentioned - Beammed Ltd. - CompuMed, Inc. - GE Healthcare - Hologic, Inc. - Lone Oak Medical Technologies, LLC For more information visit http://www.researchandmarkets.com/research/s3fz9n/bone
HOLX: 26.96 (+0.77)
The Zacks Analyst Blog Highlights: Edwards Lifesciences, Hospira, Hologic and Heartware International
PR Newswire - Thu Oct 23, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Edwards Lifesciences Corp. (NYSE:EW-Free Report), Hospira Inc. (NYSE:HSP-Free Report), Hologic Inc. (Nasdaq:HOLX-Free Report) and Heartware International Inc. (Nasdaq:HTWR-Free Report).
EW: 119.93 (-0.99), HOLX: 26.96 (+0.77)
Can Quality Systems (QSII) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 3:20PM CDT
Our proven model does not conclusively show that Quality Systems Inc. (QSII) is likely to beat earnings this quarter.
PACB: 6.56 (unch), QSII: 14.84 (-0.27), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77)
Can Edwards Lifesciences (EW) Surprise Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 2:30PM CDT
Edwards Lifesciences (EW) has delivered positive earnings surprises in all the past four quarters with an average beat of 9.7%
EW: 119.93 (-0.99), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Genetic Testing Market Outlook 2018 Featuring the Ten Most Active Genetic Testing Market Players Worldwide
M2 - Wed Oct 22, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twtv8n/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook 2018" report to their offering. A recent report, Genetic Testing Market Outlook 2018, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in this report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2013-2018. Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications. The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report. Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth. The report also profiles the ten most active genetic testing market players worldwide: Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Life Technologies, Agilent, Hologic, Illumina, Qiagen, Cepheid, and Affymetrix. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Genetic Testing Overview 4. Global Genetic Testing Market Overview 5. Disease-Wise Analysis 6. Country-Level Analysis 7. Emerging Sectors 8. Genetic Testing Regulation 9. Competitive Assessment - Abbott Laboratories - Affymetrix, Inc. - Agilent Technologies Inc. - Cepheid - Hologic, Inc. - Illumina, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Myriad Genetics, Inc. - Qiagen NV - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/tw...ic_testing
ABT: 43.29 (-0.30), MYGN: 39.48 (-0.01), A: 40.84 (-14.44), CPHD: 52.41 (-0.60), ILMN: 194.33 (+1.75), HOLX: 26.96 (+0.77), AFFX: 9.18 (+0.17)
Can Cerner Corp. (CERN) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:45PM CDT
Our proven model does not conclusively show that Cerner Corporation (CERN) is likely to beat earnings this quarter.
PACB: 6.56 (unch), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), CERN: 63.26 (-0.08)
Will Varian Medical Systems (VAR) Miss Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 12:10PM CDT
For the fourth quarter of fiscal 2014, Varian Medical Systems (VAR) expects revenues to increase in the range of 7 to 15%.
VAR: 83.76 (-0.36), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Is Thermo Fisher (TMO) Poised to Surprise Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 1:50PM CDT
Last quarter, Thermo Fisher Scientific, Inc. (TMO) had delivered a 6.17% positive surprise.
PACB: 6.56 (unch), TMO: 118.40 (+0.83), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77)
Look Down!; Jump of a Lifetime; Not for the Faint of Heart: Best of Kass
at The Street - Sun Oct 19, 3:21PM CDT
In highlights from his trading diary of the past week, Doug Kass writes about how investors aren't looking in the right direction and frustration with such a volatile market.
NFLX: 388.41 (-4.36), HLF: 55.90 (+3.44), GE: 25.70 (-0.11), HTZ: 21.91 (-0.01), TLM: 6.10 (-0.28), RIG: 28.87 (-0.96), EBAY: 52.70 (+0.20), NUAN: 15.60 (+0.17), CHK: 21.79 (-0.39), IEP: 105.26 (-0.32), AAPL: 109.40 (+1.40), HOLX: 26.96 (+0.77)
Will Intuitive Surgical (ISRG) Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 1:40PM CDT
Our proven model does not conclusively show that Intuitive Surgical, Inc. (ISRG) is likely to beat earnings this quarter.
ISRG: 495.84 (+0.04), ABAX: 52.95 (+0.29), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77)
Will athenahealth, Inc. (ATHN) Beat Earnings this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:40AM CDT
Our proven model does not conclusively show that athenahealth, Inc. (ATHN) is likely to beat earnings this quarter.
ABAX: 52.95 (+0.29), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), ATHN: 123.65 (+1.15)
Global Breast Imaging Technologies Market to 2019
M2 - Thu Oct 16, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jns6bn/breast_imaging) has announced the addition of the "Breast Imaging Technologies Market - Global Forecasts to 2019" report to their offering. The global breast imaging market holds a significant share of the medical device industry owing to rising awareness about the early screening of breast cancer. Though digital Mammography is the gold standard in the current breast imaging market, modalities such as breast MRI Scans, breast ultrasound and CTs are expected to drastically improve the breast Imaging Market scenario. This research analysis provides, a detailed information on breast imaging technological advancements in breast cancer diagnosis. This research report identifies and evaluates key advancements of breast screening modalities in development and approval stages. Patent analysis, investor analysis and investment opportunity evaluation along with multi-level criteria technology benchmarking are assessed within the breast imaging sector. Strategic recommendations for technology stakeholders are elaborately discussed in this research service. The global breast imaging market is estimated to grow at a CAGR of 8.1% in the forecast period. Global rise in the incidences and prevalence of breast cancer cases, rapid growth in aging population, development of advanced breast imaging technologies, and increasing awareness about early breast cancer screening are some of the key factors that are fueling the growth of the market. However, side effects of radiation dosage during breast imaging procedures, high installation cost of this systems, and false cancer diagnosis are some of the key factors hampering the growth of this market. Furthermore, stringent regulatory approvals for new technologies and government pressure to reduce the usage of radiation dose are some of the key challenges faced by market players. The emerging markets including China and India have become attractive for companies engaged in the development and marketing of the breast imaging technologies. Rising breast cancer awareness, government initiatives to increasing awareness about women healthcare, rising incidences of breast cancer, and increasing government investments in this technologies are the key factors propelling the demand of the this technologies in the emerging markets. In 2013, Hologic, Inc. (U.S.) held the leading position in the global mammography market. Over the past three years, the company adopted expansion of its R&D capabilities, new product launches, and strategic partnerships/agreements as its key business strategies to ensure its dominant position in this market. In addition, GE Healthcare (U.K.), Philips Healthcare (Netherlands), Siemens Healthcare (Germany), SonoCine, Inc. (U.S.), and Toshiba Corporation (Japan) are some other key players in the global mammography market. Scope of the Report By Type - Ionizing Breast Imaging Technologies - Analog Mammography - Full-Field Digital Mammography - 3D Breast Tomosynthesis - Positron Emission Tomography/Computed Tomography (PET/CT) - Molecular Breast Imaging (MBI) - Cone Beam Computed Tomography (CBCT) - Positron Emission Mammography (PEM) - Non-ionizing Breast Imaging Technologies - Breast MRI - Breast Ultrasound - Optical Imaging - Whole Breast Ultrasound - Breast Thermography Companies Mentioned - Aurora Imaging Technology, Inc. - Dilon Technologies, Inc. - Dune Medical Devices - Gamma Medica, Inc. - Ge Healthcare (Apart of General Electric Company) - Hologic, Inc. - Philips Healthcare (A Part of Konninklijke Philips N.V.) - Siemens Healthcare (A Part of Siemens AG) - Sonocine, Inc. - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/jn...st_imaging
GE: 25.70 (-0.11), HOLX: 26.96 (+0.77)
HOLX Recent Posts: http://investorshangout.com/Hologic-Inc-HOLX-54363/
HOLX Hologic Inc Recent Headline News
The Centers for Medicare and Medicaid Services Issues Ruling on 2015 Reimbursement Rates
PR Newswire - Fri Oct 31, 9:28PM CDT
Hologic, Inc. (NASDAQ: HOLX) announced today that the Centers for Medicare and Medicaid Services (CMS) has released reimbursement rates for screening and diagnostic 3D mammography. The action establishes national average payment rates for the Category I Current Procedural Terminology (CPT) code for 3D screening mammography and creates a new add-on Healthcare Common Procedure Coding System (HCPCS) code for 3D diagnostic mammography.
HOLX: 26.96 (+0.77)
Health Care Equipment Stocks Technical Insight - Medtronic, Abbott Laboratories, Hologic, ResMed, and Covidien
PR Newswire - Fri Oct 31, 8:05AM CDT
Investor-Edge has initiated coverage on the following equities: Medtronic Inc. (NYSE: MDT), Abbott Laboratories (NYSE: ABT), Hologic Inc. (NASDAQ: HOLX), ResMed Inc. (NYSE: RMD), and Covidien PLC (NYSE: COV). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 30, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,195.42, up 1.30% and the NASDAQ Composite closed at 4,566.14, up 0.37%. The S&P 500 finished the session 0.62% higher at 1,994.65. During the trading session, nine out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index gaining 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
ABT: 43.29 (-0.30), MDT: 68.15 (-0.01), COV: 92.42 (-0.02), RMD: 51.71 (-0.51), HOLX: 26.96 (+0.77)
Is Haemonetics (HAE) Poised to Beat on Q2 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:15PM CDT
Haemonetics (HAE) has delivered positive earnings surprises in three of the past four quarters with an average beat of 1.9%
HAE: 34.74 (-2.98), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Can Qiagen (QGEN) Surprise Earnings Estimates in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 5:17PM CDT
In Japan, Qiagen (QGEN) performed impressively in the first half of 2014 on a year-over-year basis.
QGEN: 23.70 (+0.24), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Luminex Tops Q3 Earnings, Revenues in Line; Outlook Weak - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:40PM CDT
Luminex Corporation's (LMNX) earnings per share jumped sharply to 22 cents from a penny in the year-ago quarter driven by strong revenue growth and margin expansion.
BDX: 127.42 (-1.28), LMNX: 18.78 (-0.22), AFFX: 9.18 (+0.17), HOLX: 26.96 (+0.77)
Upgrade Alert for Hologic (HOLX)
Comtex SmarTrend(R) - Tue Oct 28, 6:58AM CDT
Hologic (NASDAQ:HOLX) was upgraded from Hold to Buy at Craig-Hallum today. The stock closed yesterday at $25.21 on volume of 2.5 million shares, below average daily volume of 2.7 million. Over the past year, Hologic has traded in a range of $13.90 to $26.75 and closed yesterday at $25.21, 81% above that low. Over the last five market days, the 200-day moving average (MA) has gone up 0.2% while the 50-day MA has declined 0.2%.
HOLX: 26.96 (+0.77)
Can Ecolab Inc. (ECL) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:58PM CDT
Our proven model does not conclusively show that Ecolab Inc. (ECL) is likely to beat earnings this quarter.
HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68), ECL: 110.10 (-1.13)
Is LabCorp (LH) Likely to Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 2:20PM CDT
Laboratory Corp. of America Holdings (LH) is scheduled to release its third-quarter 2014 results before the opening bell on Oct 28.
LH: 101.23 (-8.06), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Axial and Peripheral Bone Densitometers - 2014 Global Strategic Business Report.
M2 - Fri Oct 24, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s3fz9n/bone) has announced the addition of the "Bone Densitometers - Global Strategic Business Report." report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 18 companies including many key and niche players. This report analyzes the worldwide markets for Bone Densitometers in Units and US$ Thousands by the following Product Segments: - Axial Bone Densitometers - Peripheral Bone Densitometers Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. Competitive Factors 3. Reimbursements: Vital For Market Expansion 4. Product Overview 5. Osteoporosis: An Overview 6. Bone Densitometry Alternatives 7. Osteoporosis Drug Market - Impact On Diagnostics 8. Recent Industry Activity 9. Focus On Select Players 10. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape - Total Companies Profiled: 18 (including Divisions/Subsidiaries - 19) - The United States (5) - Japan (1) - Europe (
- - France (2) - - Germany (1) - - The United Kingdom (1) - - Italy (1) - - Spain (1) - - Rest of Europe (2) - Asia-Pacific (Excluding Japan) (4) - Middle East (1) Companies Mentioned - Beammed Ltd. - CompuMed, Inc. - GE Healthcare - Hologic, Inc. - Lone Oak Medical Technologies, LLC For more information visit http://www.researchandmarkets.com/research/s3fz9n/bone HOLX: 26.96 (+0.77)
The Zacks Analyst Blog Highlights: Edwards Lifesciences, Hospira, Hologic and Heartware International
PR Newswire - Thu Oct 23, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Edwards Lifesciences Corp. (NYSE:EW-Free Report), Hospira Inc. (NYSE:HSP-Free Report), Hologic Inc. (Nasdaq:HOLX-Free Report) and Heartware International Inc. (Nasdaq:HTWR-Free Report).
EW: 119.93 (-0.99), HOLX: 26.96 (+0.77)
Can Quality Systems (QSII) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 3:20PM CDT
Our proven model does not conclusively show that Quality Systems Inc. (QSII) is likely to beat earnings this quarter.
PACB: 6.56 (unch), QSII: 14.84 (-0.27), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77)
Can Edwards Lifesciences (EW) Surprise Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 22, 2:30PM CDT
Edwards Lifesciences (EW) has delivered positive earnings surprises in all the past four quarters with an average beat of 9.7%
EW: 119.93 (-0.99), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Genetic Testing Market Outlook 2018 Featuring the Ten Most Active Genetic Testing Market Players Worldwide
M2 - Wed Oct 22, 9:09AM CDT
Research and Markets (http://www.researchandmarkets.com/research/twtv8n/genetic_testing) has announced the addition of the "Genetic Testing Market Outlook 2018" report to their offering. A recent report, Genetic Testing Market Outlook 2018, provides an in-depth analysis of the current and future genetic testing market. A comprehensive introduction of gene-based tests, their working principles and types are covered in this report. On account of our analysis of the past and present market trends; drivers; and existing strengths and challenges; forecast for genetic testing has been drawn, according to which, the market is likely to grow at a CAGR of around 9% during 2013-2018. Our report is an outcome of extensive interaction with industry experts which has led us to portray the updated status of genetic testing in various therapeutic areas, major geographies and significant industry applications. The genetic testing industry has seen several new product launches, active research innovations, strategic activities, launch of new DTC tests, and wider therapeutic applications. The report effectively illustrates the role of genetic testing in diseases such as Cancer, Cystic Fibrosis, and Alzheimer. It also incorporates the information on disease prevalence, available tests, and genes that cause a particular disease. An extensive research and reliable statistics in terms of market size, developments and future performance for emerging sectors namely, Next-Generation Sequencing, Whole Genome Sequencing, Non Invasive Prenatal Diagnostics, and Personalized Medicine have been covered in the report. Genetic testing is growing in both developing and developed nations with both industry and research personnel highlighting the significance of molecular biology. The report provides comprehensive analytics of key developments for major markets including the U.S., Europe and Asian countries, and their market overview. Country level analysis depicts the level of penetration for genetic testing, types of tests available, consumer perspectives, regulatory stringency and future growth. The report also profiles the ten most active genetic testing market players worldwide: Abbott Laboratories, Roche Diagnostics, Myriad Genetics, Life Technologies, Agilent, Hologic, Illumina, Qiagen, Cepheid, and Affymetrix. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Genetic Testing Overview 4. Global Genetic Testing Market Overview 5. Disease-Wise Analysis 6. Country-Level Analysis 7. Emerging Sectors 8. Genetic Testing Regulation 9. Competitive Assessment - Abbott Laboratories - Affymetrix, Inc. - Agilent Technologies Inc. - Cepheid - Hologic, Inc. - Illumina, Inc. - Life Technologies Corporation (Thermo Fisher Scientific) - Myriad Genetics, Inc. - Qiagen NV - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/tw...ic_testing
ABT: 43.29 (-0.30), MYGN: 39.48 (-0.01), A: 40.84 (-14.44), CPHD: 52.41 (-0.60), ILMN: 194.33 (+1.75), HOLX: 26.96 (+0.77), AFFX: 9.18 (+0.17)
Can Cerner Corp. (CERN) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 5:45PM CDT
Our proven model does not conclusively show that Cerner Corporation (CERN) is likely to beat earnings this quarter.
PACB: 6.56 (unch), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), CERN: 63.26 (-0.08)
Will Varian Medical Systems (VAR) Miss Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 12:10PM CDT
For the fourth quarter of fiscal 2014, Varian Medical Systems (VAR) expects revenues to increase in the range of 7 to 15%.
VAR: 83.76 (-0.36), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), HSP: 53.02 (-0.68)
Is Thermo Fisher (TMO) Poised to Surprise Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 20, 1:50PM CDT
Last quarter, Thermo Fisher Scientific, Inc. (TMO) had delivered a 6.17% positive surprise.
PACB: 6.56 (unch), TMO: 118.40 (+0.83), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77)
Look Down!; Jump of a Lifetime; Not for the Faint of Heart: Best of Kass
at The Street - Sun Oct 19, 3:21PM CDT
In highlights from his trading diary of the past week, Doug Kass writes about how investors aren't looking in the right direction and frustration with such a volatile market.
NFLX: 388.41 (-4.36), HLF: 55.90 (+3.44), GE: 25.70 (-0.11), HTZ: 21.91 (-0.01), TLM: 6.10 (-0.28), RIG: 28.87 (-0.96), EBAY: 52.70 (+0.20), NUAN: 15.60 (+0.17), CHK: 21.79 (-0.39), IEP: 105.26 (-0.32), AAPL: 109.40 (+1.40), HOLX: 26.96 (+0.77)
Will Intuitive Surgical (ISRG) Beat Q3 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 17, 1:40PM CDT
Our proven model does not conclusively show that Intuitive Surgical, Inc. (ISRG) is likely to beat earnings this quarter.
ISRG: 495.84 (+0.04), ABAX: 52.95 (+0.29), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77)
Will athenahealth, Inc. (ATHN) Beat Earnings this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 16, 8:40AM CDT
Our proven model does not conclusively show that athenahealth, Inc. (ATHN) is likely to beat earnings this quarter.
ABAX: 52.95 (+0.29), HTWR: 77.02 (-0.10), HOLX: 26.96 (+0.77), ATHN: 123.65 (+1.15)
Global Breast Imaging Technologies Market to 2019
M2 - Thu Oct 16, 3:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jns6bn/breast_imaging) has announced the addition of the "Breast Imaging Technologies Market - Global Forecasts to 2019" report to their offering. The global breast imaging market holds a significant share of the medical device industry owing to rising awareness about the early screening of breast cancer. Though digital Mammography is the gold standard in the current breast imaging market, modalities such as breast MRI Scans, breast ultrasound and CTs are expected to drastically improve the breast Imaging Market scenario. This research analysis provides, a detailed information on breast imaging technological advancements in breast cancer diagnosis. This research report identifies and evaluates key advancements of breast screening modalities in development and approval stages. Patent analysis, investor analysis and investment opportunity evaluation along with multi-level criteria technology benchmarking are assessed within the breast imaging sector. Strategic recommendations for technology stakeholders are elaborately discussed in this research service. The global breast imaging market is estimated to grow at a CAGR of 8.1% in the forecast period. Global rise in the incidences and prevalence of breast cancer cases, rapid growth in aging population, development of advanced breast imaging technologies, and increasing awareness about early breast cancer screening are some of the key factors that are fueling the growth of the market. However, side effects of radiation dosage during breast imaging procedures, high installation cost of this systems, and false cancer diagnosis are some of the key factors hampering the growth of this market. Furthermore, stringent regulatory approvals for new technologies and government pressure to reduce the usage of radiation dose are some of the key challenges faced by market players. The emerging markets including China and India have become attractive for companies engaged in the development and marketing of the breast imaging technologies. Rising breast cancer awareness, government initiatives to increasing awareness about women healthcare, rising incidences of breast cancer, and increasing government investments in this technologies are the key factors propelling the demand of the this technologies in the emerging markets. In 2013, Hologic, Inc. (U.S.) held the leading position in the global mammography market. Over the past three years, the company adopted expansion of its R&D capabilities, new product launches, and strategic partnerships/agreements as its key business strategies to ensure its dominant position in this market. In addition, GE Healthcare (U.K.), Philips Healthcare (Netherlands), Siemens Healthcare (Germany), SonoCine, Inc. (U.S.), and Toshiba Corporation (Japan) are some other key players in the global mammography market. Scope of the Report By Type - Ionizing Breast Imaging Technologies - Analog Mammography - Full-Field Digital Mammography - 3D Breast Tomosynthesis - Positron Emission Tomography/Computed Tomography (PET/CT) - Molecular Breast Imaging (MBI) - Cone Beam Computed Tomography (CBCT) - Positron Emission Mammography (PEM) - Non-ionizing Breast Imaging Technologies - Breast MRI - Breast Ultrasound - Optical Imaging - Whole Breast Ultrasound - Breast Thermography Companies Mentioned - Aurora Imaging Technology, Inc. - Dilon Technologies, Inc. - Dune Medical Devices - Gamma Medica, Inc. - Ge Healthcare (Apart of General Electric Company) - Hologic, Inc. - Philips Healthcare (A Part of Konninklijke Philips N.V.) - Siemens Healthcare (A Part of Siemens AG) - Sonocine, Inc. - Toshiba Corporation For more information visit http://www.researchandmarkets.com/research/jn...st_imaging
GE: 25.70 (-0.11), HOLX: 26.96 (+0.77)
